<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Chem Inf Model</journal-id>
    <journal-id journal-id-type="publisher-id">ci</journal-id>
    <journal-id journal-id-type="coden">jcisd8</journal-id>
    <journal-title-group>
      <journal-title>Journal of Chemical Information and Modeling</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1549-9596</issn>
    <issn pub-type="epub">1549-960X</issn>
    <publisher>
      <publisher-name>American Chemical
Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8317153</article-id>
    <article-id pub-id-type="pmid">34213323</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jcim.1c00168</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>pdCSM-cancer: Using Graph-Based Signatures to Identify
Small Molecules with Anticancer Properties</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>Al-Jarf</surname>
          <given-names>Raghad</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff3" ref-type="aff">§</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>de Sá</surname>
          <given-names>Alex G. C.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff3" ref-type="aff">§</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3004-2119</contrib-id>
        <name>
          <surname>Pires</surname>
          <given-names>Douglas E. V.</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff3" ref-type="aff">§</xref>
        <xref rid="aff5" ref-type="aff">⊥</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2948-2413</contrib-id>
        <name>
          <surname>Ascher</surname>
          <given-names>David B.</given-names>
        </name>
        <xref rid="cor2" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
        <xref rid="aff3" ref-type="aff">§</xref>
        <xref rid="aff4" ref-type="aff">∥</xref>
        <xref rid="aff6" ref-type="aff">#</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Structural
Biology and Bioinformatics, Department of Biochemistry, <institution>University of Melbourne</institution>, Parkville 3052, Victoria, <country>Australia</country></aff>
      <aff id="aff2"><label>‡</label>Systems
and Computational Biology, Bio21 Institute, <institution>University of Melbourne</institution>, Parkville 3052, Victoria, <country>Australia</country></aff>
      <aff id="aff3"><label>§</label>Computational
Biology and Clinical Informatics, <institution>Baker
Heart and Diabetes Institute</institution>, Melbourne 3004, Victoria, <country>Australia</country></aff>
      <aff id="aff4"><label>∥</label>Baker
Department of Cardiometabolic Health, Melbourne Medical School, <institution>University of Melbourne</institution>, Parkville 3010, Victoria, <country>Australia</country></aff>
      <aff id="aff5"><label>⊥</label>School
of Computing and Information Systems, <institution>University
of Melbourne</institution>, Parkville 3052, Victoria, <country>Australia</country></aff>
      <aff id="aff6"><label>#</label>Department
of Biochemistry, <institution>University of Cambridge</institution>, 80 Tennis Ct Rd, Cambridge CB2 1GA, <country>United Kingdom</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>douglas.pires@unimelb.edu.au</email>.</corresp>
      <corresp id="cor2"><label>*</label>Email: <email>david.ascher@unimelb.edu.au</email>. Tel: <phone>+61 90354794</phone>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>02</day>
      <month>07</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>26</day>
      <month>07</month>
      <year>2021</year>
    </pub-date>
    <volume>61</volume>
    <issue>7</issue>
    <fpage>3314</fpage>
    <lpage>3322</lpage>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>02</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Authors. Published by American
Chemical Society</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci1c00168_0006" id="ab-tgr1"/>
      </p>
      <p>The development of
new, effective, and safe drugs to treat cancer
remains a challenging and time-consuming task due to limited hit rates,
restraining subsequent development efforts. Despite the impressive
progress of quantitative structure–activity relationship and
machine learning-based models that have been developed to predict
molecule pharmacodynamics and bioactivity, they have had mixed success
at identifying compounds with anticancer properties against multiple
cell lines. Here, we have developed a novel predictive tool, pdCSM-cancer,
which uses a graph-based signature representation of the chemical
structure of a small molecule in order to accurately predict molecules
likely to be active against one or multiple cancer cell lines. pdCSM-cancer
represents the most comprehensive anticancer bioactivity prediction
platform developed till date, comprising trained and validated models
on experimental data of the growth inhibition concentration (GI50%)
effects, including over 18,000 compounds, on 9 tumor types and 74
distinct cancer cell lines. Across 10-fold cross-validation, it achieved
Pearson’s correlation coefficients of up to 0.74 and comparable
performance of up to 0.67 across independent, non-redundant blind
tests. Leveraging the insights from these cell line-specific models,
we developed a generic predictive model to identify molecules active
in at least 60 cell lines. Our final model achieved an area under
the receiver operating characteristic curve (AUC) of up to 0.94 on
10-fold cross-validation and up to 0.94 on independent non-redundant
blind tests, outperforming alternative approaches. We believe that
our predictive tool will provide a valuable resource to optimizing
and enriching screening libraries for the identification of effective
and safe anticancer molecules. To provide a simple and integrated
platform to rapidly screen for potential biologically active molecules
with favorable anticancer properties, we made pdCSM-cancer freely
available online at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.unimelb.edu.au/pdcsm_cancer">http://biosig.unimelb.edu.au/pdcsm_cancer</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Wellcome Trust</institution>
            <institution-id institution-id-type="doi">10.13039/100004440</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>093167/Z/10/Z</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>National Health and Medical Research Council</institution>
            <institution-id institution-id-type="doi">10.13039/501100000925</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>GNT1174405</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Medical Research Council</institution>
            <institution-id institution-id-type="doi">10.13039/501100000265</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>MR/M026302/1</award-id>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Jack Brockhoff Foundation</institution>
            <institution-id institution-id-type="doi">10.13039/100012698</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>JBF 4186, 2016</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ci1c00168</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ci1c00168</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>Cancer
is the second leading cause of death globally, responsible
for almost 10 million deaths yearly, according to the World Health
Organization.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Despite the evolution of
cancer chemotherapy for different tumor types,<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> most
existing drugs have many limitations, including undesirable side effects,
the lack of efficacy, toxicity, and resistance against current cancer
therapy.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup> This has driven the widespread and continuous
search for new effective anticancer treatments while remaining a significant
challenge to overcome.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup></p>
    <p>One limitation
of current screening strategies has been the inefficiencies
of current phenotypic and high-throughput screening approaches, which
only screen a limited portion of available chemical space and have
low hit rates of 0.01–1%, and the size of the molecules screened
is a constraint, which may limit or complicate subsequent optimization
efforts in terms of both pharmacokinetic and pharmacodynamic properties.<sup><xref ref-type="bibr" rid="ref7">7</xref>−<xref ref-type="bibr" rid="ref9">9</xref></sup> Optimizing and enriching these libraries for compounds more likely
to demonstrate anticancer potential, and promising pharmacokinetics,
could significantly reduce the associated time and development costs.
Toward this, several studies have applied statistical and machine
learning approaches in order to identify potential anticancer molecules.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup> This has been greatly aided by
the Development Therapeutics Program (DTP), which experimentally evaluated
thousands of small molecules tested against NCI-60 human cancer cell
lines.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> For example, leveraging this data,
Li and Huang used machine learning to identifying molecules with anticancer
activity,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and Kumar and colleagues had
some success developing quantitative structure–activity relationship
(QSAR) models against 16 pancreatic cancer cell lines, regardless
of the biological targets of the drugs.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> One of their limitations, however, was that no information was provided
regarding the physicochemical properties and structural features that
a molecule should have to enhance the bioactivity and cytotoxicity
against various pancreatic cell lines.</p>
    <p>Previous studies have
shown that applying the graph-based signature
approach is an efficient way to describe chemical, biomolecular data
sets and design chemical molecules. In addition, graph-based signatures
have been currently used to represent three-dimensional (3D) space
of chemical entities as well as to accurately predict their pharmacokinetics,
toxicity, and bioactivity properties.<sup><xref ref-type="bibr" rid="ref14">14</xref>−<xref ref-type="bibr" rid="ref22">22</xref></sup> Using this concept, we have developed a new machine learning tool,
pdCSM-cancer (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>), which can accurately predict small molecules that are likely to
be active against one or multiple cancer types over different cell
lines.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>pdCSM-cancer workflow. The developed approach has four major stages.
(1) In data curation, small-molecule activity data (in terms of GI50%)
were obtained from DTP of NCI<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> for nine
different tumor types (74 cancer cell lines); (2) in feature engineering,
two types of features were calculated: (i) graph-based signatures,
which represent the chemical geometry and physicochemical properties
of small molecules, and (ii) compound general properties and pharmacophores;
(3) these features were then employed to train and test predictive
models using supervised learning, and model optimization was carried
out, via greedy feature selection; (4) finally, the models with the
best performance were made available through a user-friendly web interface.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci1c00168_0002" id="gr1" position="float"/>
    </fig>
  </sec>
  <sec id="sec2">
    <title>Results and Discussion</title>
    <sec id="sec2.1">
      <title>Quantitative Correlation
of Molecular Properties with Biological
Activity</title>
      <p>A large and diverse data set of the experimental
activity of thousands of molecules against the National Cancer Institute
(NCI) 60 cancer cell lines was collected from the literature. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figure S1</ext-link> represents the distribution of physicochemical
properties for compounds with anticancer activity. Most of the active
and inactive molecules obeyed Lipinski’s rule of five,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> indicating a bias in the primary screening libraries
for anticancer drug discovery.</p>
      <p>To explore what makes a good
hit while screening for anticancer compounds, we assessed whether
there was an association between physicochemical properties and biological
activity. We observed that the active molecules tended to have a slightly
larger topological polar surface area (TPSA), more rings, and a slightly
larger number of hydrogen bond acceptors and donors (using a two-sample
Kolmogorov–Smirnov test, <italic>p</italic>-value &lt; 2.2e-16)
compared to the inactive molecules (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figure S1</ext-link>). This may represent a significant increase in the molecular complexity
needed for optimizing potency and safety while designing anticancer
molecules.</p>
    </sec>
    <sec id="sec2.2">
      <title>Molecular Substructure Mining</title>
      <p>In
order to better understand
and interpret what makes up a molecule with anticancer properties,
we investigated common substructures enriched in compounds with anticancer
activity using MoSS.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> We explored substructure
enrichment in a focused group comprising active molecules, in comparison
to a complementary set (inactive molecules). In addition, the common
substructure enrichment was examined in the NCI-60 panels of cell
lines represented as nine distinct tumor types: leukemia, central
nervous system (CNS), renal, melanoma, colon, ovarian, breast, lung,
and prostate cancers.</p>
      <p>Four common substructures were found to
be occurring more frequently in active molecules in comparison with
inactive molecules. The active molecules were found to be enriched
in benzene rings. The analysis presented in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> depicts the commonly occurring substructures.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Molecular
substructure enrichment in compounds with anticancer
activity. (A) The first fragment occurred 6.50% in active and 1.78%
in inactive molecules, tested against the CNS, ovarian, and non-small-cell
lung cancer cell panels (lines). (B) The second fragment occurred
5.95% in active and 1.86% in inactive molecules, tested against leukemia,
renal, and breast cancer cell panels. (C) The third fragment was identified
in 6.58% in active and 1.70% in inactive molecules, tested against
prostate (not shown), melanoma, and colon cancer cell lines. (D) The
fourth fragment was found in 11% in active and 2.0% in inactive compounds,
tested against small lung cancer cell lines.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci1c00168_0003" id="gr2" position="float"/>
      </fig>
      <p>The first substructure (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A) is naphthalene, which is a simple polycyclic aromatic
hydrocarbon. Chemical compounds derived from naphthalene are known
to display different biological activities, which include anticancer, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://antibacterial">antibacterial</uri>, and anti-inflammatory
activities.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> Additionally, several studies
have reported that naphthalene derivatives could induce cell apoptosis
in many types of cancer cells, such as colon cancer cells, breast
cancer cells, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://melanoma">melanoma</uri> cells, and
lung cancer cells.<sup><xref ref-type="bibr" rid="ref26">26</xref>−<xref ref-type="bibr" rid="ref28">28</xref></sup></p>
      <p>The second substructure (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>B) is the lactone structure. Several compounds
containing
lactone exhibited remarkable <italic>in vitro</italic> cytotoxic activity
as well as apoptosis against non-small cell lung, breast, and leukemia
cancer cell lines.<sup><xref ref-type="bibr" rid="ref29">29</xref>,<xref ref-type="bibr" rid="ref30">30</xref></sup></p>
      <p>The third substructure
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>C) is the <italic>N</italic>-methyl aniline structure,
which is used for designing Src kinase inhibitors. Small molecules
containing <italic>N</italic>-methyl aniline have exhibited potential
anticancer activity against different tumor types.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup></p>
      <p>The fourth substructure (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>D) is quinoline, which is an aromatic heterocyclic
compound. It consists of a benzene and a pyridine ring. Also, it is
a part of the known topoisomerase II inhibitor voreloxin.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Derivatives of quinoline have shown significant
anticancer activity by different mechanisms including apoptosis and
growth inhibition through cell cycle arrest.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></p>
    </sec>
    <sec id="sec2.3">
      <title>Predicting Small Molecules with Anticancer Activity</title>
      <p>To predict
anticancer pharmacodynamic properties of small molecules,
as well as their bioactivity, different supervised machine learning
algorithms were applied to train a classification predictive model,
using evidence from the distance-based graph signatures and more general
physicochemical properties. A diverse data set of 18,369 experimentally
characterized molecules with anticancer properties screened against
NCI-60 cancer cell lines were employed, including 8565 active and
9804 inactive molecules.</p>
      <p>In the NCI-60 DTP project, molecule
screening was carried out in two stages to discover potential anticancer
activity. Initially, all compounds were screened against 60 cancer
cell lines at 5–10 molar concentrations. Furthermore, compounds
exhibiting significant growth inhibition were evaluated on the NCI-60
cell panel at five different concentration levels.</p>
      <p>After feature
selection, our final model achieved an accuracy of
0.86 on 10-fold cross-validation, with an area under the ROC curve
(AUC) of 0.90 and a precision of 0.85 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A), significantly outperforming the alternative
approach CDRUG developed using the same data (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). This was comparable to the performance
across the non-redundant blind test, achieving an accuracy of 0.77,
AUC of 0.84, and precision of 0.79, providing confidence in the generalizability
of the final model (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Receiver operating characteristic (ROC) curves of the pdCSM-cancer
classification model. Our predictive model accurately identified active
molecules with AUC &gt; 0.84 on cross-validation and blind tests.
(A)
Performance of pdCSM-cancer on the CDRUG data. (B) Performance of
pdCSM-cancer predictor on the updated NCI-60 data.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci1c00168_0004" id="gr3" position="float"/>
      </fig>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Comparative Performance on Cross-Validation
between the pdCSM-cancer Classification Model and Another Available
Approach, CDRUG<xref rid="t1fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="left"/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">method</th>
              <th style="border:none;" align="center">MCC</th>
              <th style="border:none;" align="center" char=".">sensitivity</th>
              <th style="border:none;" align="center" char=".">FPR</th>
              <th style="border:none;" align="center">accuracy</th>
              <th style="border:none;" align="center" char=".">AUC</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">pdCSM-cancer (updated NCI-60 data)</td>
              <td style="border:none;" align="left">0.72</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">0.13</td>
              <td style="border:none;" align="left">0.86</td>
              <td style="border:none;" align="char" char=".">0.94</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">pdCSM-cancer (CDRUG data)</td>
              <td style="border:none;" align="left">0.70</td>
              <td style="border:none;" align="char" char=".">0.85</td>
              <td style="border:none;" align="char" char=".">0.15</td>
              <td style="border:none;" align="left">0.86</td>
              <td style="border:none;" align="char" char=".">0.90</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">CDRUG<sup><xref ref-type="bibr" rid="ref10">10</xref></sup></td>
              <td style="border:none;" align="left">*</td>
              <td style="border:none;" align="char" char=".">0.81</td>
              <td style="border:none;" align="char" char=".">0.20</td>
              <td style="border:none;" align="left">*</td>
              <td style="border:none;" align="char" char=".">0.87</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t1fn1">
            <label>a</label>
            <p>Asterisk: MCC and
accuracy predictive
scores were not reported by CDRUG, neither the prediction matrix (i.e.,
predicted and actual values for each molecule).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Furthermore, we tested the performance
of our final model on the
updated NCI-60 data, where it achieved an accuracy of 0.86 on 10-fold
cross-validation, AUC of 0.94, and precision of 0.84 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). On the non-redundant blind
test, it achieved an accuracy of 0.87, AUC of 0.94, and precision
of 0.85. The model performance was consistent on both data sets (the
updated NCI-60 and CDRUG data), which shows the robustness of the
method (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).</p>
      <p>A two-sample Kolmogorov–Smirnov test was conducted on all
the features used in the final model to determine which distinct features
of the compounds translate into anticancer activity. We found that
molecules with anticancer activity tended to have a high frequency
of lactone and pyridine rings (<italic>p</italic>-value &lt; 1.9 e-07).
Interestingly, the inactive compounds tended to have a higher frequency
of amides. These characteristics were further validated by substructure
mining. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figure S2</ext-link> depicts the top discriminative
features of active compounds compared to inactive compounds.</p>
    </sec>
    <sec id="sec2.4">
      <title>Cell Line-Specific
Activity Prediction</title>
      <p>While the performance
of our approach to identify likely generic anticancer compounds provided
further confidence into the potential of graph-based signatures to
provide biological insight, cancer is not a single disease. We therefore
applied this approach to predict the anticancer activity (GI50%) against
each of the 74 specific cancer cell lines. The final models achieved
Pearson’s correlation coefficients ranging from 0.58 (for SNB-78
cell line) to 0.74 (for P388 cell line) across 10-fold cross validation
(<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Table S2</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figures S3–S12</ext-link>). Similarly, Cortés-Ciriano and colleagues modeled the 50%
growth inhibition (GI50%) of thousands of compounds screened against
59 cancer cell lines of the NCI60 panel, and by combining chemical
and biological information, their models achieved a mean Pearson’s
correlations ranging from 0.41 (for LOCCO: leave-one-compound-out
model) and 0.88 (for LOTO: leave-one-tissue-out model).<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> The results obtained for our final models are
comparable to the performance reported previously.</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Performance of the Final pdCSM-Cancer
Regression Models on Cross-Validation and Blind Test Sets</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">tissue</th>
              <th style="border:none;" align="center">cell lines</th>
              <th style="border:none;" align="center" char=".">Pearson (CV)</th>
              <th style="border:none;" align="center" char=".">Pearson
(blind test)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="8" style="border:none;" align="left">CNS</td>
              <td style="border:none;" align="left">SF-268</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SF-295</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SF-539</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SNB-19</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.61</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SNB-75</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SNB-78</td>
              <td style="border:none;" align="char" char=".">0.61</td>
              <td style="border:none;" align="char" char=".">0.52</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">U251</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.63</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">XF-498</td>
              <td style="border:none;" align="char" char=".">0.60</td>
              <td style="border:none;" align="char" char=".">0.51</td>
            </tr>
            <tr>
              <td rowspan="6" style="border:none;" align="left">breast</td>
              <td style="border:none;" align="left">BT-549</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HS-578 T</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.54</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MCF7</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MDA-MB-231_ATCC</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MDA-MB-468</td>
              <td style="border:none;" align="char" char=".">0.58</td>
              <td style="border:none;" align="char" char=".">0.49</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">T-47D</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td rowspan="9" style="border:none;" align="left">colon</td>
              <td style="border:none;" align="left">COLO-205</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">DLD-1</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HCC-2998</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.63</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HCT-116</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.61</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HCT-15</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HT29</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.65</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">KM12</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">KM20L2</td>
              <td style="border:none;" align="char" char=".">0.62</td>
              <td style="border:none;" align="char" char=".">0.53</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SW-620</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td rowspan="8" style="border:none;" align="left">leukemia</td>
              <td style="border:none;" align="left">CCRF-CEM</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HL-60 TB</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">K-562</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.57</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MOLT-4</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">P388_ADR</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.67</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">P388</td>
              <td style="border:none;" align="char" char=".">0.74</td>
              <td style="border:none;" align="char" char=".">0.65</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">RPMI-8226</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SR</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.62</td>
            </tr>
            <tr>
              <td rowspan="7" style="border:none;" align="left">ovarian</td>
              <td style="border:none;" align="left">IGROV1</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.57</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">NCI_ADR-RES</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">OVCAR-3</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">OVCAR-4</td>
              <td style="border:none;" align="char" char=".">0.63</td>
              <td style="border:none;" align="char" char=".">0.62</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">OVCAR-5</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.54</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">OVCAR-8</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SK-OV-3</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.57</td>
            </tr>
            <tr>
              <td rowspan="2" style="border:none;" align="left">prostate</td>
              <td style="border:none;" align="left">DU-145</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">PC-3</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td rowspan="10" style="border:none;" align="left">renal</td>
              <td style="border:none;" align="left">786-0</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">A498</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.63</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">ACHN</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">CAKI-1</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">RXF-393</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">RXF-631</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.63</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SN12C</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SN12K1</td>
              <td style="border:none;" align="char" char=".">0.74</td>
              <td style="border:none;" align="char" char=".">0.65</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">TK-10</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.61</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">UO-31</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.55</td>
            </tr>
            <tr>
              <td rowspan="11" style="border:none;" align="left">non-small cell lung</td>
              <td style="border:none;" align="left">A549_ATCC</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">EKVX</td>
              <td style="border:none;" align="char" char=".">0.62</td>
              <td style="border:none;" align="char" char=".">0.53</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HOP-18</td>
              <td style="border:none;" align="char" char=".">0.54</td>
              <td style="border:none;" align="char" char=".">0.48</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HOP-62</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">HOP-92</td>
              <td style="border:none;" align="char" char=".">0.60</td>
              <td style="border:none;" align="char" char=".">0.57</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">LXFL-529</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">NCI-H226</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.54</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">NCI-H23</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">NCI-H322M</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.67</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">NCI-H460</td>
              <td style="border:none;" align="char" char=".">0.69</td>
              <td style="border:none;" align="char" char=".">0.63</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">NCI-H522</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.57</td>
            </tr>
            <tr>
              <td rowspan="2" style="border:none;" align="left">small cell lung</td>
              <td style="border:none;" align="left">DMS-114</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">DMS-273</td>
              <td style="border:none;" align="char" char=".">0.58</td>
              <td style="border:none;" align="char" char=".">0.48</td>
            </tr>
            <tr>
              <td rowspan="11" style="border:none;" align="left">melanoma</td>
              <td style="border:none;" align="left">LOX-IMVI</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">M14</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.58</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">M19-MEL</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MALME-3 M</td>
              <td style="border:none;" align="char" char=".">0.64</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MDA-MB-435</td>
              <td style="border:none;" align="char" char=".">0.68</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MDA-N</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.61</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SK-MEL-28</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SK-MEL-2</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.56</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">SK-MEL-5</td>
              <td style="border:none;" align="char" char=".">0.66</td>
              <td style="border:none;" align="char" char=".">0.64</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">UACC-257</td>
              <td style="border:none;" align="char" char=".">0.65</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">UACC-62</td>
              <td style="border:none;" align="char" char=".">0.67</td>
              <td style="border:none;" align="char" char=".">0.59</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p><xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref> depicts
the performance in terms of predicted <italic>versus</italic> experimental
GI50% values<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> for each model for 10-fold
cross-validation, also highlighting performance on 90% of the data
(i.e<italic>.</italic>, after 10% outlier removal).</p>
      <fig id="fig4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>pdCSM-cancer regression
performance on cross-validation. Scatter
plots between experimental and predicted GI50% values, given in −log<sub>10</sub>(molar), for each of the nine cancer cell line (panels) models
are displayed. Pearson’s correlation coefficient (<italic>r</italic>) is shown for each scatter plot (in black for 90% of the data, after
10% of outliers (depicted in red) were removed).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci1c00168_0005" id="gr4" position="float"/>
      </fig>
      <p>To further validate the models, these were evaluated on independent
blind tests sets. The performance was observed to be consistent between
cross-validation and blind tests, indicating the generalization capabilities
of the models. For blind tests, the models achieved Pearson’s
correlations ranging from 0.48 (DMS-273 cell line) and 0.67 (P388_ADR
cell line) (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figures S13–S22</ext-link>).</p>
      <p>Comparison
of the distributions of the predicted <italic>versus</italic> experimental
GI50% values<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> for each
model of the 74 specific cancer cell lines revealed that there was
a significant overlap of compounds with an experimental −log<sub>10</sub>(GI50%) value of 4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figures S3–S22</ext-link>), indicating a low anti-proliferative activity against all types
of cancer cell lines tested, which might impose a bias and, as a consequence,
a challenge for the regression models in predicting anticancer activity.
To account for this, a general classifier model was built that is
capable of predicting anticancer and non-anticancer molecules, as
described above. To the best of our knowledge, this is the first effort
of developing cancer cell line-specific bioactivity predictors using
the NCI-60 panels.</p>
      <p>Compounds that are active on a given tissue
type could display
similar molecular signatures against other cancer types and their
activity could be a reflection of similar chemical structures.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Therefore, we examined whether cancer types could
be clustered based on common molecular features between compounds.
We performed a clustering analysis based on <italic>k</italic>-means
and hierarchical agglomerative clustering on the 74 specific cancer
cell lines. Interestingly, the clustering analysis revealed that the
cell lines per tissue type do not cluster together, apart from a group
of melanoma cell lines that tended to form a small cluster. Nevertheless,
even if the cell line has a distinct identity, the properties of a
given data set might be subject to sampling biases or may not match
the cancer type of origin. The latter may be because tumors that are
supposed to arise in a particular tissue could be a metastatic lesion
arising from a distal site. Consequently, cell lines originating from
such tumors might have a different tissue type identification from
that specified at isolation, creating a cause of mislabeling.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figure S23</ext-link> shows
a heatmap of the distinctive molecular features between different
cancer cell lines.</p>
    </sec>
    <sec id="sec2.5">
      <title>pdCSM-cancer Web Server</title>
      <p>To provide
the scientific community
with pdCSM-cancer functionalities, we have implemented an easy-to-use
web interface freely available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.unimelb.edu.au/pdcsm_cancer">http://biosig.unimelb.edu.au/pdcsm_cancer</uri>. Users can predict the anticancer activity and GI50% values of their
molecules of interest by submitting either a single molecule or multiple
molecules as a batch file by presenting molecules as SMILES strings.</p>
      <p>Additionally, it allows users to calculate the pharmacokinetic
properties of their chosen molecules using the pkCSM tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figure S24</ext-link>).</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Conclusions</title>
    <p>Here,
we have presented pdCSM-cancer, an optimized graph-based
signature approach for predicting safe, efficient, and biologically
active compounds against multiple cancer types. pdCSM-cancer is capable
of quantitatively predicting small molecules that are likely to be
active against one or multiple cancer cell lines.</p>
    <p>Using graph-based
signatures, we have built and implemented 74
regression models capable of quantitatively assessing molecule bioactivity
and a predictive classification model with categorical outputs for
predicting anticancer activity for novel molecules as well as their
physicochemical properties. We have made pdCSM-cancer available through
a user-friendly web server at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.unimelb.edu.au/pdcsm_cancer">http://biosig.unimelb.edu.au/pdcsm_cancer</uri>.</p>
    <p>We believe that pdCSM-cancer would be a valuable tool for
augmenting
screening approaches to identifying novel anticancer drugs, increasing
hit rates and reducing costs. This will hopefully facilitate the process
of drug discovery by enabling the rapid design and optimization of
compounds with anticancer properties.</p>
    <p>As future work, we intend
to investigate the association of combined
drugs<sup><xref ref-type="bibr" rid="ref37">37</xref>,<xref ref-type="bibr" rid="ref38">38</xref></sup> (i.e., molecules) to improve the efficiency
of cancer treatments. Our further study would seek to understand how
the anticancer bioactivity of a certain compound changes when it interacts
with others. In addition, to incorporate more interpretability into
pdCSM-cancer, we aim to predict not only the anticancer property for
that particular drug but also hierarchically its respective target(s).<sup><xref ref-type="bibr" rid="ref39">39</xref>−<xref ref-type="bibr" rid="ref42">42</xref></sup> With this, drug treatments may be more understandable in terms of
efficiency and side effects, for instance. Finally, further development
of a molecular generative model (e.g., conditional variational autoencoder)<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> will be carried out. Autoencoders would provide
the ability to test/screen drugs that are out of the scope of the
database (e.g., NCI-60). This would likely yield novel drugs with
anticancer properties, which have not been tested yet.</p>
  </sec>
  <sec id="sec4">
    <title>Methods</title>
    <sec id="sec4.1">
      <title>Data Sets</title>
      <p>All datasets were curated from the NCI-60
Development Therapeutics Project (DTP),<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> which has thousands of small molecules analyzed against NCI-60 human
cancer cell lines. In this fashion, to develop a general bioactivity
predictor, first, a dataset of bioactive molecules with anticancer
properties were constructed from an updated version of NCI-60 data
(June 2020). The data for constructing the updated version of the
anticancer bioactivity dataset can be retrieved from NCI DTP on NCI-60
Growth Inhibition Data.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> The construction
of this first dataset was based on the same methodology used by Li
and Huang’s study<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> and comprehends
12,646 active and 15,777 inactive molecules after merging with Li
and Huang’s previous benchmark data. Second, for direct comparison
with the CDRUG approach, Li and Huang’s dataset was solely
employed to test the predictive performance of pdCSM-cancer. This
benchmark data comprises 8565 active and 9804 inactive molecules.</p>
      <p>It is worth noting that the bioactivity in both datasets is defined
based on one dose and dose-response data. On these dose data, a molecule
is considered as inactive if the average of the growth inhibition
rate is lower than 5% at a dose of 10<sup>–5</sup> mol on one
dose data. On the other hand, a molecule is set as active if the average
of the growth inhibition rate is higher than 50% at a dose of 10<sup>–5</sup> mol on dose-response data.</p>
      <p>Experimental GI50%
(50% of cell growth inhibition) values, given
in −log<sub>10</sub>(molar), for the NCI-60 human cancer cell
lines were also collected from the NCI-60 Development Therapeutics
Project,<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> including 15,636 experimental
results against the 60 different cancer cell lines (plus 14 additional
cancer cell lines) derived from nine tumor types. This data was used
as evidence to train cell line-specific learning models for regression
tasks and assess their final predictive/generalization performance.
The negative logarithm of the GI50% values of each molecule was combined
(based on NCI identifiers) for each cancer cell line to generate tissue-specific
data sets, which included at least 7677 unique molecules.</p>
      <p>The
bioactivity and GI50% datasets were divided into a non-redundant
training (80%) and blind test (20%) to train and evaluate the predictive/generalization
performance of the predictive models used for the classification and
regression tasks. Molecules were clustered on Morgan/Circular fingerprints
with the Butina algorithm using Tanimoto similarity (at a 0.6 similarity
level) using RDKit<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> to make sure that
similar molecules were either on training or test sets. All datasets
used in this study are available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.unimelb.edu.au/pdcsm_cancer/data">http://biosig.unimelb.edu.au/pdcsm_cancer/data</uri>.</p>
    </sec>
    <sec id="sec4.2">
      <title>Graph-Based Signatures to Represent Small Molecules</title>
      <p>Graph
modeling is a well-established mathematical representation
used to model chemical entities, which relies on the structural fingerprints
of molecular descriptors to determine the relationships between molecular
structures and their biological activities. These signatures have
been proven to be a general and powerful tool to model the physicochemical
properties of small molecules<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> and other
biological entities.<sup><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref44">44</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> We have previously proposed the concept of graph-based signatures
to represent protein structure geometry and the molecular interactions
with their binding partners as graphs.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref46">46</xref>−<xref ref-type="bibr" rid="ref49">49</xref></sup> These were successfully used and adapted to train and test many
different machine learning models, such as the prediction and optimization
of pharmacokinetic and toxicity properties using a pkCSM tool.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> We employed and adapted these distance-based
signatures to model small-molecule chemistry, enabling the prediction
of their anticancer properties.</p>
      <p>There are two key components
of the graph-based signatures: (i) compound physicochemical properties
obtained via the RDKit cheminformatics library<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> and (ii) distance-based signatures, described as a cumulative
distribution function of distances in atoms defined based on their
corresponding physicochemical properties (pharmacophores) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Table S1</ext-link>). The distance-based patterns are encoded
in a small-molecule graph-based signature that was adjusted from the
Cutoff Scanning matrix method.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> In this
approach, each dimension of the molecular signature expresses the
number of atoms (characterized by pharmacophore class) within a particular
distance in the graph. The cost of the shortest path is based on the
shortest distance between any two nodes in the molecular graph, calculated
by Johnson’s algorithm. It is described as the total weights
of the edges on the path, where all the edges are considered to have
unitary weight (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Figure S25</ext-link>). Hence, the
value of the shortest path is expressed as the number of edges in
it.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Using the graph-based signature approach,
a total of 264 features were obtained and used to train and test the
predictive models.</p>
      <p>It is worth noting that there are other ways
to represent small
molecules in order to build machine learning for molecular prediction.
For instance, one of the current approaches is based on deep feature
generation through graph neural networks (GNN).<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Although being a successful approach, GNN-generated features
have, as a major drawback, the lack of an inherent interpretability,
which is a natural aspect from the graph-based signatures. Accordingly,
graph-based signature features were first preferred for pdCSM-cancer
than others. In future work, other types of features (e.g., deep GNN
features) will be incorporated into the pdCSM-cancer models after
carrying out an analysis of their predictive benefits.</p>
    </sec>
    <sec id="sec4.3">
      <title>Feature Selection</title>
      <p>Selecting the best set of features
to train predictive models is known to be a challenging problem. A
bottom-up greedy feature selection method was employed to reduce the
redundancy, noise, and low representativity of the 264 graph-based
signature features obtained to represent molecules.</p>
      <p>This method
starts with zero features, by considering each feature independently,
adds them one by one in accordance to a machine learning model, and
keeps only the set of features with the most prominent performance
metric (e.g., Pearson’s correlation coefficient) on that particular
model.</p>
    </sec>
    <sec id="sec4.4">
      <title>Model Selection and Evaluation</title>
      <p>To obtain a predictive
classification model, we first evaluated several learning algorithms,
including random forest, extremely randomized trees, gradient boosting, <italic>k</italic>-nearest neighbors, and extreme gradient boosting, using
the implementation available on the Scikit-learn library.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> Random forest was the one with the best predictive
performance on 10-fold cross-validation over the training set after
greedy feature selection. Therefore, the random forest classifier
was used as our final model.</p>
      <p>Random forest is a powerful ensemble-learning
algorithm that generates multiple models of decision trees from a
randomly chosen subset of the training set. It then aggregates the
votes from various decision trees to determine the most voted class
of the test object.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> The predictive model
was trained and assessed using 10-fold cross-validation and a non-redundant
blind test. The model performance was evaluated using different evaluation
metrics, which include accuracy, precision, and the area under the
ROC curve (AUC). AUC is an effective measure to evaluate a model’s
performance in a classification task at various threshold settings.
It is based on the ROC curve, which is plotted with the true positive
rate (TPR) against the false positive rate (FPR). Higher AUC means
that the model is robust and capable of discriminating between the
two classes: active and inactive. AUC uses values between 0 and 1.
Therefore, an accurate model would have an AUC of 1, and an AUC of
0.5 indicates that the model is a random classifier.</p>
      <p>In the
regression counterpart of this work, we also analyzed different
regression supervised learning methods to build 74 models for predicting
the GI50% values, including gradient boosting, extreme gradient boosting,
random forest, extremely randomized trees, and adaptive boosting,
which were applied via the Scikit-learn library.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> Pearson’s correlation coefficient, RMSE, and Kendall’s
correlation coefficient were employed to select the model with the
best performance (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Table S2</ext-link>) after greedy
feature selection. A 10-fold cross-validation procedure and non-redundant
blind test were employed to evaluate the performance of the predictive
models. To examine the effect of potential outliers, the model’s
performance was evaluated on 100% and also on 90% of the data, which
can be interpreted as the full data set minus the 10% worst predicted
data points (i.e<italic>.</italic>, the points that fall away from
the regression line). For the datasets, the ensemble methods, extremely
randomized trees and random forest, were found to be the best performing
algorithms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">Table S2</ext-link>).</p>
    </sec>
    <sec id="sec4.5">
      <title>Substructure
Mining</title>
      <p>Molecular Substructure miner (MoSS)<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> was used to investigate the substructure enrichment
in molecules with anticancer activity. We examined frequent substructures
in a focused group including active molecules, in comparison to a
complementary set (inactive molecules). To find the frequency of substructure
enrichment in a set of molecules, we used a minimum support (frequency)
of 10% (default) in the focus set and a 2% of the maximum support
(frequency) in complement. Also, the threshold for the split was specified
as 0.5.</p>
    </sec>
    <sec id="sec4.6">
      <title>Web Server Development</title>
      <p>The web server front end was
developed via Bootstrap framework
version 3.3.7, and the back end was built in Python 2.7 with the use
of the Flask framework (version 0.12.3). It is hosted on a Linux server
running Apache.</p>
    </sec>
  </sec>
</body>
<back>
  <notes id="notes2" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jcim.1c00168?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.1c00168</ext-link>.<list id="silist" list-type="simple"><list-item><p>Physiochemical properties
and distribution of compounds;
pdCSM-cancer blind test and cross-validation results; heatmap of common
molecular properties in the NCI60 panels; pdCSM-cancer web server
interface; complementary features applied in pdCSM-cancer development;
performance of pdCSM-cancer using different evaluation metrics; and
graph-based signatures calculations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jcim.1c00168/suppl_file/ci1c00168_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ci1c00168_si_001.pdf">
        <caption>
          <p>ci1c00168_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="funding-statement" id="notes3">
    <p>R.A. is funded
with a PhD scholarship from the Kingdom of Saudi Arabia. A.G.C.S.
acknowledges the Joe White Bequest Fellowship for its support. This
work was supported in part by the Medical Research Council (MR/M026302/1
to D.B.A. and D.E.V.P.); the National Health and Medical Research
Council of Australia (GNT1174405 to D.B.A.), the Wellcome Trust (093167/Z/10/Z),
Jack Brockhoff Foundation (JBF 4186, 2016 to D.B.A.), and the Victorian
Government’s Operational Infrastructure Support Program. For
the purpose of open access, the author has applied a CC BY public
copyright licence to any Author Accepted Manuscript version arising
from this submission.</p>
  </notes>
  <notes notes-type="COI-statement" id="NOTES-d7e1401-autogenerated">
    <p>The authors declare no
competing financial interest.</p>
  </notes>
  <notes notes-type="" id="notes1">
    <title>Notes</title>
    <p>All data
sets used in this study to train and
validate the predictive models are freely available at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.unimelb.edu.au/pdcsm_cancer/data">http://biosig.unimelb.edu.au/pdcsm_cancer/data</uri>. Our predictive model pdCSM-cancer is freely available as a user-friendly
web interface at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biosig.unimelb.edu.au/pdcsm_cancer">http://biosig.unimelb.edu.au/pdcsm_cancer</uri>.</p>
  </notes>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="undeclared" id="cit1"><person-group person-group-type="allauthors"><name><surname>World Health</surname><given-names>O.</given-names></name></person-group><source>Cancer</source>; <comment><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Https://Www.Who.Int/En/News-Room/Fact-Sheets/Detail/Cancer">Https://Www.Who.Int/En/News-Room/Fact-Sheets/Detail/Cancer</uri></comment>. <italic>WHO/CDS/CSR/GAR/2003.11</italic><year>2003</year>.</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>McQuade</surname><given-names>R. M.</given-names></name>; <name><surname>Stojanovska</surname><given-names>V.</given-names></name>; <name><surname>Bornstein</surname><given-names>J. C.</given-names></name>; <name><surname>Nurgali</surname><given-names>K.</given-names></name><article-title>Colorectal Cancer Chemotherapy:
The Evolution of Treatment and New Approaches</article-title>. <source>Curr. Med. Chem.</source><year>2017</year>, <fpage>1537</fpage><pub-id pub-id-type="doi">10.2174/0929867324666170111152436</pub-id>.<pub-id pub-id-type="pmid">28079003</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Quinn</surname><given-names>D. I.</given-names></name>; <name><surname>Sandler</surname><given-names>H. M.</given-names></name>; <name><surname>Horvath</surname><given-names>L. G.</given-names></name>; <name><surname>Goldkorn</surname><given-names>A.</given-names></name>; <name><surname>Eastham</surname><given-names>J. A.</given-names></name><article-title>The Evolution
of Chemotherapy for the Treatment of Prostate Cancer</article-title>. <source>Annl Oncol.</source><year>2017</year>, <fpage>2658</fpage><pub-id pub-id-type="doi">10.1093/annonc/mdx348</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Kibria</surname><given-names>G.</given-names></name>; <name><surname>Hatakeyama</surname><given-names>H.</given-names></name>; <name><surname>Harashima</surname><given-names>H.</given-names></name><article-title>Cancer Multidrug Resistance: Mechanisms
Involved and Strategies for Circumvention Using a Drug Delivery System</article-title>. <source>Arch. Pharmacal Res.</source><year>2014</year>, <fpage>4</fpage><pub-id pub-id-type="doi">10.1007/s12272-013-0276-2</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Singh</surname><given-names>H.</given-names></name>; <name><surname>Kumar</surname><given-names>R.</given-names></name>; <name><surname>Singh</surname><given-names>S.</given-names></name>; <name><surname>Chaudhary</surname><given-names>K.</given-names></name>; <name><surname>Gautam</surname><given-names>A.</given-names></name>; <name><surname>Raghava</surname><given-names>G. P. S.</given-names></name><article-title>Prediction of
Anticancer Molecules
Using Hybrid Model Developed on Molecules Screened against Nci-60
Cancer Cell Lines</article-title>. <source>BMC Cancer</source><year>2016</year>, <volume>16</volume>, <fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s12885-016-2082-y</pub-id>.<pub-id pub-id-type="pmid">26860193</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Cui</surname><given-names>W.</given-names></name>; <name><surname>Aouidate</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>S.</given-names></name>; <name><surname>Yu</surname><given-names>Q.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Yuan</surname><given-names>S.</given-names></name><article-title>Discovering Anti-Cancer Drugs Via Computational Methods</article-title>. <source>Front. Pharmacol.</source><year>2020</year>, <volume>11</volume>, <fpage>733</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00733</pub-id>.<pub-id pub-id-type="pmid">32508653</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Reymond</surname><given-names>J. L.</given-names></name>; <name><surname>Awale</surname><given-names>M.</given-names></name><article-title>Exploring Chemical
Space for Drug Discovery Using the Chemical Universe
Database</article-title>. <source>ACS Chem. Neurosci.</source><year>2012</year>, <fpage>649</fpage><pub-id pub-id-type="doi">10.1021/cn3000422</pub-id>.<pub-id pub-id-type="pmid">23019491</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Moffat</surname><given-names>J. G.</given-names></name>; <name><surname>Rudolph</surname><given-names>J.</given-names></name>; <name><surname>Bailey</surname><given-names>D.</given-names></name><article-title>Phenotypic
Screening in Cancer Drug
Discovery-Past, Present and Future</article-title>. <source>Nat. Rev.
Drug Discovery</source><year>2014</year>, <fpage>588</fpage><pub-id pub-id-type="doi">10.1038/nrd4366</pub-id>.<pub-id pub-id-type="pmid">25033736</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Hoelder</surname><given-names>S.</given-names></name>; <name><surname>Clarke</surname><given-names>P. A.</given-names></name>; <name><surname>Workman</surname><given-names>P.</given-names></name><article-title>Discovery of Small Molecule Cancer
Drugs: Successes, Challenges and Opportunities</article-title>. <source>Mol. Oncol.</source><year>2012</year>, <fpage>155</fpage><pub-id pub-id-type="doi">10.1016/j.molonc.2012.02.004</pub-id>.<pub-id pub-id-type="pmid">22440008</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Li</surname><given-names>G. H.</given-names></name>; <name><surname>Huang</surname><given-names>J. F.</given-names></name><article-title>Cdrug: A Web Server for Predicting
Anticancer Activity
of Chemical Compounds</article-title>. <source>Bioinformatics</source><year>2012</year>, <volume>28</volume>, <fpage>3334</fpage>–<lpage>3335</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts625</pub-id>.<pub-id pub-id-type="pmid">23080119</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Menden</surname><given-names>M. P.</given-names></name>; <name><surname>Iorio</surname><given-names>F.</given-names></name>; <name><surname>Garnett</surname><given-names>M.</given-names></name>; <name><surname>McDermott</surname><given-names>U.</given-names></name>; <name><surname>Benes</surname><given-names>C. H.</given-names></name>; <name><surname>Ballester</surname><given-names>P. J.</given-names></name>; <name><surname>Saez-Rodriguez</surname><given-names>J.</given-names></name><article-title>Machine Learning
Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and
Chemical Properties</article-title>. <source>PLoS One</source><year>2013</year>, <volume>8</volume>, <fpage>e61318</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0061318</pub-id>.<pub-id pub-id-type="pmid">23646105</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Shoemaker</surname><given-names>R. H.</given-names></name><article-title>The Nci60
Human Tumour Cell Line Anticancer Drug Screen</article-title>. <source>Nat. Rev. Cancer</source><year>2006</year>, <volume>6</volume>, <fpage>813</fpage>–<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1038/nrc1951</pub-id>.<pub-id pub-id-type="pmid">16990858</pub-id></mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Kumar</surname><given-names>R.</given-names></name>; <name><surname>Chaudhary</surname><given-names>K.</given-names></name>; <name><surname>Singla</surname><given-names>D.</given-names></name>; <name><surname>Gautam</surname><given-names>A.</given-names></name>; <name><surname>Raghava</surname><given-names>G. P. S.</given-names></name><article-title>Designing
of Promiscuous Inhibitors against Pancreatic Cancer Cell Lines</article-title>. <source>Sci. Rep.</source><year>2015</year>, <volume>4</volume>, <fpage>4668</fpage><pub-id pub-id-type="doi">10.1038/srep04668</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Csm-Lig: A Web Server
for Assessing and Comparing Protein-Small
Molecule Affinities</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>, <volume>44</volume>, <fpage>W557</fpage>–<lpage>W561</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw390</pub-id>.<pub-id pub-id-type="pmid">27151202</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Blundell</surname><given-names>T. L.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Pkcsm: Predicting Small-Molecule
Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures</article-title>. <source>J. Med. Chem.</source><year>2015</year>, <volume>58</volume>, <fpage>4066</fpage>–<lpage>4072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id>.<pub-id pub-id-type="pmid">25860834</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Mycocsm: Using Graph-Based Signatures to Identify Safe
Potent Hits against Mycobacteria</article-title>. <source>J. Chem. Inf.
Model.</source><year>2020</year>, <fpage>3450</fpage><pub-id pub-id-type="doi">10.1021/acs.jcim.0c00362</pub-id>.<pub-id pub-id-type="pmid">32615035</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="undeclared" id="cit17"><person-group person-group-type="allauthors"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Stubbs</surname><given-names>K. A.</given-names></name>; <name><surname>Mylne</surname><given-names>J. S.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name></person-group><article-title>Designing Safe
and Potent Herbicides with the Cropcsm Online Resource</article-title>. <source>bioRxiv</source><year>2020</year>, 2020.11.01.364240.</mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Kaminskas</surname><given-names>L. M.</given-names></name>; <name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Dendpoint: A Web
Resource for Dendrimer
Pharmacokinetics Investigation and Prediction</article-title>. <source>Sci. Rep.</source><year>2019</year>, <volume>9</volume>, <fpage>15465</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-51789-3</pub-id>.<pub-id pub-id-type="pmid">31664080</pub-id></mixed-citation>
    </ref>
    <ref id="ref19">
      <mixed-citation publication-type="journal" id="cit19"><name><surname>Rodrigues</surname><given-names>C. H. M.</given-names></name>; <name><surname>Myung</surname><given-names>Y.</given-names></name>; <name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Mcsm-Ppi2: Predicting
the Effects of Mutations on Protein-Protein Interactions</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <fpage>W338</fpage><pub-id pub-id-type="doi">10.1093/nar/gkz383</pub-id>.<pub-id pub-id-type="pmid">31114883</pub-id></mixed-citation>
    </ref>
    <ref id="ref20">
      <mixed-citation publication-type="journal" id="cit20"><person-group person-group-type="allauthors"><name><surname>Jiang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>R.</given-names></name>; <name><surname>Wei</surname><given-names>G. W.</given-names></name></person-group><article-title>Ggl-Tox: Geometric Graph Learning
for Toxicity Prediction</article-title>. <source>J. Chem. Inf. Model.</source><year>2021</year>.</mixed-citation>
    </ref>
    <ref id="ref21">
      <mixed-citation publication-type="journal" id="cit21"><name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Ramsundar</surname><given-names>B.</given-names></name>; <name><surname>Feinberg</surname><given-names>E. N.</given-names></name>; <name><surname>Gomes</surname><given-names>J.</given-names></name>; <name><surname>Geniesse</surname><given-names>C.</given-names></name>; <name><surname>Pappu</surname><given-names>A. S.</given-names></name>; <name><surname>Leswing</surname><given-names>K.</given-names></name>; <name><surname>Pande</surname><given-names>V.</given-names></name><article-title>Moleculenet: A Benchmark
for Molecular Machine Learning</article-title>. <source>Chem. Sci.</source><year>2018</year>, <volume>9</volume>, <fpage>513</fpage>–<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1039/C7SC02664A</pub-id>.<pub-id pub-id-type="pmid">29629118</pub-id></mixed-citation>
    </ref>
    <ref id="ref22">
      <mixed-citation publication-type="journal" id="cit22"><name><surname>Winter</surname><given-names>R.</given-names></name>; <name><surname>Montanari</surname><given-names>F.</given-names></name>; <name><surname>Noe</surname><given-names>F.</given-names></name>; <name><surname>Clevert</surname><given-names>D. A.</given-names></name><article-title>Learning Continuous
and Data-Driven Molecular Descriptors by Translating Equivalent Chemical
Representations</article-title>. <source>Chem. Sci.</source><year>2019</year>, <volume>10</volume>, <fpage>1692</fpage>–<lpage>1701</lpage>. <pub-id pub-id-type="doi">10.1039/C8SC04175J</pub-id>.<pub-id pub-id-type="pmid">30842833</pub-id></mixed-citation>
    </ref>
    <ref id="ref23">
      <note id="cit23">
        <p>
          <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-60+Data+Download+-+Previous+Releases">https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-60+Data+Download+-+Previous+Releases</uri>
        </p>
      </note>
    </ref>
    <ref id="ref24">
      <mixed-citation publication-type="journal" id="cit24"><name><surname>Lipinski</surname><given-names>C. A.</given-names></name>; <name><surname>Lombardo</surname><given-names>F.</given-names></name>; <name><surname>Dominy</surname><given-names>B. W.</given-names></name>; <name><surname>Feeney</surname><given-names>P. J.</given-names></name><article-title>Experimental and
Computational Approaches to Estimate Solubility and Permeability in
Drug Discovery and Development Settings</article-title>. <source>Adv.
Drug Delivery Rev.</source><year>2001</year>, <fpage>3</fpage><pub-id pub-id-type="doi">10.1016/S0169-409X(00)00129-0</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref25">
      <mixed-citation publication-type="book" id="cit25"><person-group person-group-type="allauthors"><name><surname>Borgelt</surname><given-names>C.</given-names></name>; <name><surname>Meinl</surname><given-names>T.</given-names></name>; <name><surname>Berthold</surname><given-names>M.</given-names></name></person-group><article-title>Moss: A Program for Molecular
Substructure Mining</article-title>. <source>Proceedings of the ACM
SIGKDD International Conference on Knowledge Discovery and Data Mining</source><italic>;</italic><publisher-name>ACM Digital Library</publisher-name><year>2005</year>, <fpage>6</fpage>–<lpage>15</lpage>.</mixed-citation>
    </ref>
    <ref id="ref26">
      <mixed-citation publication-type="journal" id="cit26"><name><surname>Xu</surname><given-names>W. T.</given-names></name>; <name><surname>Shen</surname><given-names>G. N.</given-names></name>; <name><surname>Luo</surname><given-names>Y. H.</given-names></name>; <name><surname>Piao</surname><given-names>X. J.</given-names></name>; <name><surname>Wang</surname><given-names>J. R.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>J. Q.</given-names></name>; <name><surname>Feng</surname><given-names>Y. C.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>S. N.</given-names></name>; <name><surname>Wang</surname><given-names>C. Y.</given-names></name>; <name><surname>Jin</surname><given-names>C. H.</given-names></name><article-title>New Naphthalene Derivatives Induce
Human Lung Cancer
A549 Cell Apoptosis Via Ros-Mediated Mapks, Akt, and Stat3 Signaling
Pathways</article-title>. <source>Chem.-Biol. Interact.</source><year>2019</year>, <fpage>148</fpage><pub-id pub-id-type="doi">10.1016/j.cbi.2019.03.004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref27">
      <mixed-citation publication-type="journal" id="cit27"><name><surname>Kretschmer</surname><given-names>N.</given-names></name>; <name><surname>Rinner</surname><given-names>B.</given-names></name>; <name><surname>Deutsch</surname><given-names>A. J. A.</given-names></name>; <name><surname>Lohberger</surname><given-names>B.</given-names></name>; <name><surname>Knausz</surname><given-names>H.</given-names></name>; <name><surname>Kunert</surname><given-names>O.</given-names></name>; <name><surname>Blunder</surname><given-names>M.</given-names></name>; <name><surname>Boechzelt</surname><given-names>H.</given-names></name>; <name><surname>Schaider</surname><given-names>H.</given-names></name>; <name><surname>Bauer</surname><given-names>R.</given-names></name><article-title>Naphthoquinones from
Onosma Paniculata
Induce Cell-Cycle Arrest and Apoptosis in Melanoma Cells</article-title>. <source>J. Nat. Prod.</source><year>2012</year>, <volume>75</volume>, <fpage>865</fpage>–<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1021/np2006499</pub-id>.<pub-id pub-id-type="pmid">22530779</pub-id></mixed-citation>
    </ref>
    <ref id="ref28">
      <mixed-citation publication-type="journal" id="cit28"><name><surname>Hae</surname><given-names>J. K.</given-names></name>; <name><surname>Jung</surname><given-names>Y. M.</given-names></name>; <name><surname>Young</surname><given-names>J. C.</given-names></name>; <name><surname>Kyung</surname><given-names>H. C.</given-names></name>; <name><surname>Sung</surname><given-names>W. H.</given-names></name>; <name><surname>Mie</surname><given-names>Y. K.</given-names></name><article-title>Effects of a Naphthoquinone
Analog on Tumor Growth
and Apoptosis Induction</article-title>. <source>Arch. Pharmacal Res.</source><year>2003</year>, <volume>26</volume>, <fpage>405</fpage>–<lpage>410</lpage>.</mixed-citation>
    </ref>
    <ref id="ref29">
      <mixed-citation publication-type="journal" id="cit29"><name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Wu</surname><given-names>K.</given-names></name>; <name><surname>Xu</surname><given-names>A.</given-names></name>; <name><surname>Jiao</surname><given-names>P.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Xing</surname><given-names>L.</given-names></name><article-title>The Sesquiterpene
Lactone Eupatolide Induces Apoptosis in Non-Small Cell Lung Cancer
Cells by Suppressing Stat3 Signaling</article-title>. <source>Environ.
Toxicol. Pharmacol.</source><year>2021</year>, <volume>81</volume>, <fpage>103513</fpage><pub-id pub-id-type="doi">10.1016/j.etap.2020.103513</pub-id>.<pub-id pub-id-type="pmid">33091599</pub-id></mixed-citation>
    </ref>
    <ref id="ref30">
      <mixed-citation publication-type="journal" id="cit30"><name><surname>Gach-Janczak</surname><given-names>K.</given-names></name>; <name><surname>Drogosz-Stachowicz</surname><given-names>J.</given-names></name>; <name><surname>Dlugosz-Pokorska</surname><given-names>A.</given-names></name>; <name><surname>Jakubowski</surname><given-names>R.</given-names></name>; <name><surname>Janecki</surname><given-names>T.</given-names></name>; <name><surname>Szymanski</surname><given-names>J.</given-names></name>; <name><surname>Janecka</surname><given-names>A.</given-names></name><article-title>A New Hybrid Delta-Lactone
Induces Apoptosis and Potentiates Anticancer Activity of Taxol in
Hl-60 Human Leukemia Cells</article-title>. <source>Molecules</source><year>2020</year>, <volume>25</volume>, <fpage>1479</fpage><pub-id pub-id-type="doi">10.3390/molecules25071479</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref31">
      <mixed-citation publication-type="journal" id="cit31"><name><surname>Rao</surname><given-names>V. K.</given-names></name>; <name><surname>Chhikara</surname><given-names>B. S.</given-names></name>; <name><surname>Shirazi</surname><given-names>A. N.</given-names></name>; <name><surname>Tiwari</surname><given-names>R.</given-names></name>; <name><surname>Parang</surname><given-names>K.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name><article-title>3-Substitued Indoles: One-Pot Synthesis
and Evaluation of Anticancer
and Src Kinase Inhibitory Activities</article-title>. <source>Bioorg.
Med. Chem. Lett.</source><year>2011</year>, <volume>21</volume>, <fpage>3511</fpage>–<lpage>3514</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2011.05.010</pub-id>.<pub-id pub-id-type="pmid">21612925</pub-id></mixed-citation>
    </ref>
    <ref id="ref32">
      <mixed-citation publication-type="journal" id="cit32"><name><surname>Hawtin</surname><given-names>R. E.</given-names></name>; <name><surname>Stockett</surname><given-names>D. E.</given-names></name>; <name><surname>Byl</surname><given-names>J. A. W.</given-names></name>; <name><surname>McDowell</surname><given-names>R. S.</given-names></name>; <name><surname>Nguyen</surname><given-names>T.</given-names></name>; <name><surname>Arkin</surname><given-names>M. R.</given-names></name>; <name><surname>Conroy</surname><given-names>A.</given-names></name>; <name><surname>Yang</surname><given-names>W.</given-names></name>; <name><surname>Osheroff</surname><given-names>N.</given-names></name>; <name><surname>Fox</surname><given-names>J. A.</given-names></name><article-title>Voreloxin Is an
Anticancer Quinolone Derivative That
Intercalates DNA and Poisons Topoisomerase Ii</article-title>. <source>PLoS One</source><year>2010</year>, <volume>5</volume>, <elocation-id>e10186</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0010186</pub-id>.<pub-id pub-id-type="pmid">20419121</pub-id></mixed-citation>
    </ref>
    <ref id="ref33">
      <mixed-citation publication-type="journal" id="cit33"><name><surname>Katariya</surname><given-names>K. D.</given-names></name>; <name><surname>Shah</surname><given-names>S. R.</given-names></name>; <name><surname>Reddy</surname><given-names>D.</given-names></name><article-title>Anticancer,
Antimicrobial Activities
of Quinoline Based Hydrazone Analogues: Synthesis, Characterization
and Molecular Docking</article-title>. <source>Bioorg. Chem.</source><year>2020</year>, <fpage>103406</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.103406</pub-id>.<pub-id pub-id-type="pmid">31718889</pub-id></mixed-citation>
    </ref>
    <ref id="ref34">
      <mixed-citation publication-type="journal" id="cit34"><name><surname>Cortes-Ciriano</surname><given-names>I.</given-names></name>; <name><surname>van Westen</surname><given-names>G. J.</given-names></name>; <name><surname>Bouvier</surname><given-names>G.</given-names></name>; <name><surname>Nilges</surname><given-names>M.</given-names></name>; <name><surname>Overington</surname><given-names>J. P.</given-names></name>; <name><surname>Bender</surname><given-names>A.</given-names></name>; <name><surname>Malliavin</surname><given-names>T. E.</given-names></name><article-title>Improved Large-Scale Prediction of
Growth Inhibition Patterns Using the Nci60 Cancer Cell Line Panel</article-title>. <source>Bioinformatics</source><year>2015</year>, <volume>32</volume>, <fpage>85</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btv529</pub-id>.<pub-id pub-id-type="pmid">26351271</pub-id></mixed-citation>
    </ref>
    <ref id="ref35">
      <mixed-citation publication-type="journal" id="cit35"><name><surname>Holbeck</surname><given-names>S. L.</given-names></name>; <name><surname>Collins</surname><given-names>J. M.</given-names></name>; <name><surname>Doroshow</surname><given-names>J. H.</given-names></name><article-title>Analysis
of Food and Drug Administration-Approved
Anticancer Agents in the Nci60 Panel of Human Tumor Cell Lines</article-title>. <source>Mol. Cancer Ther.</source><year>2010</year>, <volume>9</volume>, <fpage>1451</fpage>–<lpage>1460</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0106</pub-id>.<pub-id pub-id-type="pmid">20442306</pub-id></mixed-citation>
    </ref>
    <ref id="ref36">
      <mixed-citation publication-type="journal" id="cit36"><name><surname>Salvadores</surname><given-names>M.</given-names></name>; <name><surname>Fuster-Tormo</surname><given-names>F.</given-names></name>; <name><surname>Supek</surname><given-names>F.</given-names></name><article-title>Matching Cell Lines with Cancer Type
and Subtype of Origin Via Mutational, Epigenomic, and Transcriptomic
Patterns</article-title>. <source>Sci. Adv.</source><year>2020</year>, <volume>6</volume>, <fpage>eaba1862</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aba1862</pub-id>.<pub-id pub-id-type="pmid">32937430</pub-id></mixed-citation>
    </ref>
    <ref id="ref37">
      <mixed-citation publication-type="journal" id="cit37"><name><surname>Zagidullin</surname><given-names>B.</given-names></name>; <name><surname>Aldahdooh</surname><given-names>J.</given-names></name>; <name><surname>Zheng</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Saad</surname><given-names>J.</given-names></name>; <name><surname>Malyutina</surname><given-names>A.</given-names></name>; <name><surname>Jafari</surname><given-names>M.</given-names></name>; <name><surname>Tanoli</surname><given-names>Z.</given-names></name>; <name><surname>Pessia</surname><given-names>A.</given-names></name>; <name><surname>Tang</surname><given-names>J.</given-names></name><article-title>Drugcomb: An Integrative Cancer Drug
Combination Data Portal</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <volume>47</volume>, <fpage>W43</fpage>–<lpage>W51</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz337</pub-id>.<pub-id pub-id-type="pmid">31066443</pub-id></mixed-citation>
    </ref>
    <ref id="ref38">
      <mixed-citation publication-type="journal" id="cit38"><name><surname>Holbeck</surname><given-names>S. L.</given-names></name>; <name><surname>Camalier</surname><given-names>R.</given-names></name>; <name><surname>Crowell</surname><given-names>J. A.</given-names></name>; <name><surname>Govindharajulu</surname><given-names>J. P.</given-names></name>; <name><surname>Hollingshead</surname><given-names>M.</given-names></name>; <name><surname>Anderson</surname><given-names>L. W.</given-names></name>; <name><surname>Polley</surname><given-names>E.</given-names></name>; <name><surname>Rubinstein</surname><given-names>L.</given-names></name>; <name><surname>Srivastava</surname><given-names>A.</given-names></name>; <name><surname>Wilsker</surname><given-names>D.</given-names></name>; <name><surname>Collins</surname><given-names>J. M.</given-names></name>; <name><surname>Doroshow</surname><given-names>J. H.</given-names></name><article-title>The National
Cancer Institute Almanac: A Comprehensive Screening Resource for the
Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity</article-title>. <source>Cancer Res.</source><year>2017</year>, <volume>77</volume>, <fpage>3564</fpage>–<lpage>3576</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0489</pub-id>.<pub-id pub-id-type="pmid">28446463</pub-id></mixed-citation>
    </ref>
    <ref id="ref39">
      <mixed-citation publication-type="journal" id="cit39"><name><surname>Gfeller</surname><given-names>D.</given-names></name>; <name><surname>Grosdidier</surname><given-names>A.</given-names></name>; <name><surname>Wirth</surname><given-names>M.</given-names></name>; <name><surname>Daina</surname><given-names>A.</given-names></name>; <name><surname>Michielin</surname><given-names>O.</given-names></name>; <name><surname>Zoete</surname><given-names>V.</given-names></name><article-title>Swisstargetprediction: A Web Server for Target Prediction of Bioactive
Small Molecules</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>, <volume>42</volume>, <fpage>W32</fpage>–<lpage>W38</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku293</pub-id>.<pub-id pub-id-type="pmid">24792161</pub-id></mixed-citation>
    </ref>
    <ref id="ref40">
      <mixed-citation publication-type="journal" id="cit40"><name><surname>Daina</surname><given-names>A.</given-names></name>; <name><surname>Michielin</surname><given-names>O.</given-names></name>; <name><surname>Zoete</surname><given-names>V.</given-names></name><article-title>Swisstargetprediction: Updated Data
and New Features for Efficient Prediction of Protein Targets of Small
Molecules</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <volume>47</volume>, <fpage>W357</fpage>–<lpage>W364</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz382</pub-id>.<pub-id pub-id-type="pmid">31106366</pub-id></mixed-citation>
    </ref>
    <ref id="ref41">
      <mixed-citation publication-type="journal" id="cit41"><name><surname>Hamad</surname><given-names>S.</given-names></name>; <name><surname>Adornetto</surname><given-names>G.</given-names></name>; <name><surname>Naveja</surname><given-names>J. J.</given-names></name>; <name><surname>Chavan Ravindranath</surname><given-names>A.</given-names></name>; <name><surname>Raffler</surname><given-names>J.</given-names></name>; <name><surname>Campillos</surname><given-names>M.</given-names></name><article-title>Hitpickv2: A Web Server to Predict
Targets of Chemical Compounds</article-title>. <source>Bioinformatics</source><year>2019</year>, <volume>35</volume>, <fpage>1239</fpage>–<lpage>1240</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty759</pub-id>.<pub-id pub-id-type="pmid">30169615</pub-id></mixed-citation>
    </ref>
    <ref id="ref42">
      <mixed-citation publication-type="journal" id="cit42"><name><surname>Tang</surname><given-names>J.</given-names></name>; <name><surname>Szwajda</surname><given-names>A.</given-names></name>; <name><surname>Shakyawar</surname><given-names>S.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Hintsanen</surname><given-names>P.</given-names></name>; <name><surname>Wennerberg</surname><given-names>K.</given-names></name>; <name><surname>Aittokallio</surname><given-names>T.</given-names></name><article-title>Making Sense
of Large-Scale Kinase
Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis</article-title>. <source>J. Chem. Inf. Model.</source><year>2014</year>, <volume>54</volume>, <fpage>735</fpage>–<lpage>743</lpage>. <pub-id pub-id-type="doi">10.1021/ci400709d</pub-id>.<pub-id pub-id-type="pmid">24521231</pub-id></mixed-citation>
    </ref>
    <ref id="ref43">
      <mixed-citation publication-type="journal" id="cit43"><name><surname>Lim</surname><given-names>J.</given-names></name>; <name><surname>Ryu</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>J. W.</given-names></name>; <name><surname>Kim</surname><given-names>W. Y.</given-names></name><article-title>Molecular Generative Model Based
on Conditional Variational Autoencoder for De Novo Molecular Design</article-title>. <source>Aust. J. Chem.</source><year>2018</year>, <volume>10</volume>, <fpage>31</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0286-7</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref44">
      <mixed-citation publication-type="journal" id="cit44"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Mcsm-Ab: A Web Server
for Predicting Antibody-Antigen
Affinity Changes Upon Mutation with Graph-Based Signatures</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>, <volume>44</volume>, <fpage>W469</fpage>–<lpage>W473</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw458</pub-id>.<pub-id pub-id-type="pmid">27216816</pub-id></mixed-citation>
    </ref>
    <ref id="ref45">
      <mixed-citation publication-type="journal" id="cit45"><name><surname>Rodrigues</surname><given-names>C. H. M.</given-names></name>; <name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Dynamut2: Assessing Changes in Stability
and Flexibility Upon Single and Multiple Point Missense Mutations</article-title>. <source>Protein Sci.</source><year>2021</year>, <volume>30</volume>, <fpage>60</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1002/pro.3942</pub-id>.<pub-id pub-id-type="pmid">32881105</pub-id></mixed-citation>
    </ref>
    <ref id="ref46">
      <mixed-citation publication-type="journal" id="cit46"><person-group person-group-type="allauthors"><name><surname>Myung</surname><given-names>Y.</given-names></name>; <name><surname>Rodrigues</surname><given-names>C. H. M.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name>; <name><surname>Pires</surname><given-names>D. E. V.</given-names></name></person-group><article-title>Mcsm-Ab2:
Guiding Rational Antibody Design Using Graph-Based Signatures</article-title>. <source>Bioinformatics</source><year>2020</year>.</mixed-citation>
    </ref>
    <ref id="ref47">
      <mixed-citation publication-type="journal" id="cit47"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Blundell</surname><given-names>T. L.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Mcsm-Lig: Quantifying the Effects
of Mutations on Protein-Small Molecule Affinity in Genetic Disease
and Emergence of Drug Resistance</article-title>. <source>Sci. Rep.</source><year>2016</year>, <volume>6</volume>, <fpage>29575</fpage><pub-id pub-id-type="doi">10.1038/srep29575</pub-id>.<pub-id pub-id-type="pmid">27384129</pub-id></mixed-citation>
    </ref>
    <ref id="ref48">
      <mixed-citation publication-type="journal" id="cit48"><name><surname>Pires</surname><given-names>D. E. V.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Mcsm-Na: Predicting the Effects of Mutations on Protein-Nucleic
Acids Interactions</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>, <fpage>W241</fpage><pub-id pub-id-type="doi">10.1093/nar/gkx236</pub-id>.<pub-id pub-id-type="pmid">28383703</pub-id></mixed-citation>
    </ref>
    <ref id="ref49">
      <mixed-citation publication-type="journal" id="cit49"><name><surname>Rodrigues</surname><given-names>C. H.</given-names></name>; <name><surname>Pires</surname><given-names>D. E.</given-names></name>; <name><surname>Ascher</surname><given-names>D. B.</given-names></name><article-title>Dynamut:
Predicting the Impact of
Mutations on Protein Conformation, Flexibility and Stability</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>, <volume>46</volume>, <fpage>W350</fpage>–<lpage>W355</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky300</pub-id>.<pub-id pub-id-type="pmid">29718330</pub-id></mixed-citation>
    </ref>
    <ref id="ref50">
      <mixed-citation publication-type="undeclared" id="cit50"><person-group person-group-type="allauthors"><name><surname>Landrum</surname><given-names>G.</given-names></name></person-group><source>Rdkit: Open-Source Cheminformatics</source>. <year>2006</year>.</mixed-citation>
    </ref>
    <ref id="ref51">
      <mixed-citation publication-type="journal" id="cit51"><name><surname>Pires</surname><given-names>D. E.</given-names></name>; <name><surname>de Melo-Minardi</surname><given-names>R. C.</given-names></name>; <name><surname>dos Santos</surname><given-names>M. A.</given-names></name>; <name><surname>da Silveira</surname><given-names>C. H.</given-names></name>; <name><surname>Santoro</surname><given-names>M. M.</given-names></name>; <name><surname>Meira</surname><given-names>W.</given-names><suffix>Jr.</suffix></name><article-title>Cutoff Scanning Matrix
(Csm): Structural Classification and Function Prediction by Protein
Inter-Residue Distance Patterns</article-title>. <source>BMC Genomics</source><year>2011</year>, <volume>12</volume>, <fpage>S12</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-12-S4-S12</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref52">
      <mixed-citation publication-type="journal" id="cit52"><name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Guan</surname><given-names>J.</given-names></name>; <name><surname>Zhou</surname><given-names>S.</given-names></name><article-title>Fragat: A Fragment-Oriented
Multi-Scale
Graph Attention Model for Molecular Property Prediction</article-title>. <source>Bioinformatics</source><year>2021</year>, <fpage>btab195</fpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btab195</pub-id>.<pub-id pub-id-type="pmid">33769437</pub-id></mixed-citation>
    </ref>
    <ref id="ref53">
      <mixed-citation publication-type="journal" id="cit53"><name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Phung</surname><given-names>D.</given-names></name><article-title>Journal of Machine
Learning Research: Preface</article-title>. <source>J. Mach. Learn.
Res.</source><year>2014</year>, <volume>39</volume>, <fpage>i</fpage>–<lpage>ii</lpage>.</mixed-citation>
    </ref>
    <ref id="ref54">
      <mixed-citation publication-type="journal" id="cit54"><name><surname>Riddick</surname><given-names>G.</given-names></name>; <name><surname>Song</surname><given-names>H.</given-names></name>; <name><surname>Ahn</surname><given-names>S.</given-names></name>; <name><surname>Walling</surname><given-names>J.</given-names></name>; <name><surname>Borges-Rivera</surname><given-names>D.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Fine</surname><given-names>H. A.</given-names></name><article-title>Predicting
in Vitro Drug Sensitivity
Using Random Forests</article-title>. <source>Bioinformatics</source><year>2011</year>, <fpage>220</fpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq628</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref55">
      <mixed-citation publication-type="book" id="cit55"><person-group person-group-type="allauthors"><name><surname>Müller</surname><given-names>A. C.</given-names></name>; <name><surname>Guido</surname><given-names>S.</given-names></name></person-group><source>Introduction
to Machine Learning with Python</source>; <publisher-name>O’Reilly
Media</publisher-name>. <year>2017</year>; p <fpage>121</fpage>–<lpage>130</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
